Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,021 recruiting studies in this area right now.
By phase
- Not applicable2,807
- Phase 2752
- Phase 1522
- Phase 3382
- Phase 1/Phase 2294
- Phase 4205
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,192
- Melanoma175
- Metastatic Breast Cancer138
- Rheumatoid Arthritis132
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Breast Neoplasms111
- Triple Negative Breast Cancer111
- Colorectal Cancer94
- Ovarian Cancer92
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer59
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Novartis Pharmaceuticals49
- Memorial Sloan Kettering Cancer Center48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University35
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona152
- Alabama129
- Florida126
- New York111
- Texas106
- Maryland95
- Massachusetts88
- Pennsylvania72
- North Carolina67
Recruiting studies5,021 total
- NCT06623396RecruitingPhase 1
Mesothelin-targeted CAR T cells for esophagogastric cancer or mesothelioma
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
Basking Ridge, New JerseyAges 18 years+ - NCT07726342RecruitingPhase 2
Study of a new drug for advanced HER2-positive breast cancer
This study tests a new drug, SMP-656, for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if it can help shrink or control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07876349Recruiting
Genetic testing program for breast and ovarian cancer risk
This study tests a program that helps primary care doctors identify women who may benefit from genetic testing for hereditary breast and ovarian cancer. The program uses family history to guide testing and aims to make it easier for patients to get tested.
New York, New YorkAges 21–75 - NCT07203729RecruitingPhase 2
A new drug for advanced breast cancer with severe symptoms
This trial tests a new drug called SHR-A1811 (a type of targeted therapy) for people with advanced breast cancer that is HER2-low and is causing severe symptoms (visceral crisis). The drug is given alone and aims to control the cancer and relieve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07436663RecruitingPhase 4
Preventing heart damage from breast cancer chemotherapy with two diabetes drugs
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Tanta, ElgharbeyaAges Any age - NCT07678372Recruiting
Ozoaqua for abdominal scar healing after surgery
This trial tests whether Ozoaqua, a special treatment, helps heal abdominal scars better than standard care after open surgery. It may reduce scarring and improve how the scar looks and feels.
Pamplona, NavarreAges 18 years+ - NCT07681271RecruitingPhase 2
Testing Remibrutinib for papulopustular rosacea
This study tests an experimental drug called remibrutinib (taken as a pill) to see if it can safely reduce the redness and bumps caused by papulopustular rosacea. It is for people with moderate to severe symptoms who have not had success with other treatments.
El Paso, TexasAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Beverly Hills, CaliforniaAges 18 years+ - NCT07482787RecruitingPhase 3
Study of SD-101 for epidermolysis bullosa in children
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
Rancho Santa Margarita, CaliforniaAges 4 weeks–12 years - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT07386743RecruitingPhase 3
New injection for moderate-to-severe eczema
This study tests a new injection called GS101 compared to an existing treatment (Dupixent) for people with moderate-to-severe atopic dermatitis (eczema). If you join, you may receive either the new drug or the standard treatment, and researchers will track how well it controls your symptoms.
Shenyang, LiaoningAges 18–75 - NCT07754786RecruitingPhase 3
Comparing a new eczema medicine with dupilumab
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
Guangzhou, GuangdongAges 18–75 - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT07765888RecruitingPhase 3
Tilrekimig for moderate-to-severe eczema
This study tests an investigational medicine called Tilrekimig for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with standard treatments. It aims to see if the medicine can reduce symptoms and improve quality of life.
Birmingham, AlabamaAges 12 years+ - NCT07029828RecruitingPhase 3
Long-term study of ritlecitinib for severe alopecia areata in children
This study tests a medicine called ritlecitinib for children with severe alopecia areata (a condition causing hair loss). It is for kids who have already completed a previous study of this medicine to see how well it works and how safe it is over a longer period.
Irvine, CaliforniaAges 6–14 - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT07445087Recruiting
Takhzyro for hereditary angioedema in teenagers and adults
This study is for people in South Korea with hereditary angioedema. It looks at how well the drug Takhzyro works and how safe it is for teenagers and adults who are already using it or will start using it.
Suwon, Gyeonggi-doAges 12 years+ - NCT02504853Recruiting
Study food allergy patterns and genetics over time
This study follows people with food allergy and some closely related or healthy people to learn how food allergy (and related conditions) develops over time. It may help researchers find causes and better ways to predict and treat food allergy.
Bethesda, MarylandAges 1 day–99 years - NCT00001373Recruiting
Understanding the genetics of autoinflammatory diseases
This study collects genetic samples and medical histories from people with autoinflammatory diseases (like Familial Mediterranean Fever), their relatives, and healthy volunteers to understand how these conditions run in families and what causes them. Participation mainly involves providing a mail-in DNA sample.
Washington D.C., District of ColumbiaAges 2 months–115 years - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT05263206RecruitingPhase 3
Shot medicine (dupilumab) for severe, unexplained chronic itching
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
Bakersfield, CaliforniaAges 18–90 - NCT06915168Recruiting
Nerve symptom decision aid for breast cancer patients
This study tests a decision aid tool that helps people with breast cancer and nerve-related side effects from chemotherapy (like numbness or tingling) make better choices about their treatment. If you're on your third round of taxane chemo and have these symptoms, this tool may help you talk with your doctor.
Ann Arbor, MichiganAges Any age - NCT01185132RecruitingPhase 3
IMRT versus partial-breast radiation after lumpectomy
This study compares two different ways of giving radiation to the breast after lumpectomy for early-stage breast cancer. It may help determine which approach controls the cancer well while reducing radiation to surrounding healthy tissue.
Aurora, ColoradoAges 40 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,021 recruiting dermatology studies from the U.S. registry right now, out of 7,720 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.